Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in. | February 2, 2023
Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech's autonomy and flexibility in manufacturing
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and machine
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UKBioNTech aims to design and roll out randomized
Investegate announcements from BioNTech SE, BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030